DelveInsight’s “Acute Pain Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Acute Pain pipeline landscapes. It comprises Acute Pain pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Pain therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Pain pipeline products.
Some of the key takeaways of the Acute Pain Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Dsuvia (Sufentanil), Zynrelef (HTX-011), Zipsor, Ubrogepant, Oliceridine injection (TRV130), etc., are developing therapies for the treatment of Acute Pain.
-
Emerging therapies such as AcelRx Pharmaceuticals, Heron Therapeutics, Depomed, Allergan, Trevena, are expected to have a significant impact on the Acute Pain market in the coming years.
Get an overview of pipeline landscape @ Acute Pain Clinical Trials Analysis
Acute Pain Overview
Acute pain is defined as “an expected physiologic experience of injurious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.” The presence of pain often means that something is wrong. Each individual is the best judge of his or her own pain. There are different types of pain; basically, they are categorized into two forms, i.e., acute pain and chronic pain.
Acute Pain Emerging Drugs
-
Dsuvia (Sufentanil): AcelRx Pharmaceuticals
-
Zynrelef (HTX-011): Heron Therapeutics
-
Zipsor: Depomed
-
Ubrogepant: Allergan
-
Oliceridine injection (TRV130): Trevena
For further information, refer to the detailed report @ Acute Pain Pipeline Therapeutics
Scope of Acute Pain Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Dsuvia (Sufentanil), Zynrelef (HTX-011), Zipsor, Ubrogepant, Oliceridine injection (TRV130), and others.
-
Pipeline Therapies: AcelRx Pharmaceuticals, Heron Therapeutics, Depomed, Allergan, Trevena, and others.
Table of Contents
|
1 |
Acute Pain Report Introduction |
|
2 |
Acute Pain Executive Summary |
|
3 |
Acute Pain Overview |
|
4 |
Acute Pain- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Acute Pain Pipeline Therapeutics |
|
6 |
Acute Pain Late Stage Products (Phase II/III) |
|
7 |
Acute Pain Mid Stage Products (Phase II) |
|
8 |
Acute Pain Early Stage Products (Phase I) |
|
9 |
Acute Pain Preclinical Stage Products |
|
10 |
Acute Pain Therapeutic Assessment |
|
11 |
Acute Pain Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Acute Pain Key Companies |
|
14 |
Acute Pain Key Products |
|
15 |
Acute Pain Unmet Needs |
|
16 |
Acute Pain Market Drivers and Barriers |
|
17 |
Acute Pain Future Perspectives and Conclusion |
|
18 |
Acute Pain Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Acute Pain Drugs Pipeline Report
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/